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E-mail address: russ.altman@stanford.edu (R.B. AltThere is debate about the utility of clinical data warehouses for research. Using a clinical warfarin dosing
algorithm derived from research-quality data, we evaluated the data quality of both a general-purpose
database and a coagulation-speciﬁc database. We evaluated the functional utility of these repositories
by using data extracted from them to predict warfarin dose. We reasoned that high-quality clinical data
would predict doses nearly as accurately as research data, while poor-quality clinical data would predict
doses less accurately. We evaluated the Mean Absolute Error (MAE) in predicted weekly dose as a metric
of data quality. The MAE was comparable between the clinical gold standard (10.1 mg/wk) and the spe-
cialty database (10.4 mg/wk), but the MAE for the clinical warehouse was 40% greater (14.1 mg/wk). Our
results indicate that the research utility of clinical data collected in focused clinical settings is greater
than that of data collected during general-purpose clinical care.
 2010 Elsevier Inc. All rights reserved.1. Introduction
The value of clinical data and clinical data warehouses for re-
search is controversial. On one hand, they integrate information
from multiple sources, such as patient charts, radiology reports,
and laboratory results, and offer a centralized resource for access-
ing multiple data sources. Compared to most large clinical studies,
querying these databases does not require a substantial commit-
ment of time or resources, making them a potentially useful tool
for hypothesis testing. Simple queries can identify thousands of re-
cords, granting these studies signiﬁcant statistical power. Never-
theless, the quality of this data is subject to the realities and
variations in clinical practice, and is not equivalent to the data in
a research clinical trial. These issues have become particularly
important in the setting of many population-based efforts in geno-
mic discovery [1,2]. In these efforts, large clinical data repositories
are used to search for potential associations between clinical phe-
notypes and genetic markers [3]. They rest on the assumption that
the quality of the clinical phenotypes derived from clinical dat-
abases will be sufﬁciently high to provide detectable signals. Thus,
the purpose of this study was to test the accuracy of clinical data
collected and stored in an enterprise-wide data warehouse withll rights reserved.
engineering, Stanford Univer-
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man).clinical data collected and stored in a specialty clinic focusing on
the variables of interest. In particular, we used the performance
of a clinical algorithm for estimating the dose of warfarin as a func-
tional measure of data quality. We asked whether data extracted
from the general clinical database or the specialty clinic database
could be used to estimate warfarin doses with accuracies compara-
ble to that observed in research-grade data.
Warfarin is an anticoagulant taken by 30millionAmericans,with
2million new starts per year [4]. The therapeutic range of the drug is
narrow, as a high dose can lead to hemorrhage,while a lowdose fails
to protect against thromboembolism. As a result, it is one of the top
three drugs leading to emergency department visits by the elderly,
accounting for 17.3% of such visits [5]. Warfarin is dosed by trial-
and-error. Patients are initially given a ﬁxed 5 mg starting dose. On
each subsequent visit, the International Normalized Ratio (INR) is
used to measure clotting time, and warfarin dose is gradually ad-
justed using this test until a stable dose is achieved. This usually oc-
curswhen the INR value is between2.0 and 3.0. Clinical factors, such
as height,weight, age, and race, affect the ﬁnal therapeutic dose. The
International Warfarin Pharmacogenetics Consortium (IWPC) has
developed two algorithms that predict warfarin dose, one that uses
both genetic and clinical factors and another that uses only clinical
factors [6]. We focus on the algorithm using clinical factors in this
work because genetic data is not yet routinely stored in clinical dat-
abases. The key clinical factors are age, weight, ethnic background,
use of amiodarone, and use of other drugs known to induce the





Duplicate records (some records 
correspond to a different visit by the 
same patient).
Taking 5 mg/day (standard starting dose) 
or 1 mg/day (standard fixed dose).
Did not have all the variables necessary 
to predict a therapeutic dose (height 
weight, age, and race).
1098 records
Starting/stopping treatment, short 
treatment duration, dose 
changed/unstable, ambiguous wording, 
no dose available.
Fig. 1. Flow diagram for the patient selection procedure.
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error of 10.1 mg/week on a diverse global population of more than
5000 patients taking warfarin.
STRIDE is a clinical datawarehouse created for researchpurposes,
but based on clinical data collected during the provision of care. The
data model for STRIDE is based upon the Health Level Seven Refer-
ence InformationModel, and it uses SNOMEDCTand theNational Li-
brary of Medicine’s Uniﬁed Medical Language System, UMLS [7]. As
of April 2009, STRIDE contains over 7.5million full-text clinical doc-
uments. This database permits clinical data extraction, yielding
thousands of short excerpts de-identiﬁed of personal information.
STRIDE offers substantial data integration, allowing investigators
to ask arbitrary questions across diseases and cohorts.
The CoagClinic database is maintained by a hematologist and
pharmacists who specialize in anticoagulation [8]. Moreover, the
database itself is designed with warfarin therapy in mind. This
database contains the dose and INR values from every visit, ICD-
9 codes for each diagnosis, target INR goal, complete pharmacy re-
cords, and the physician notes from each visit. In order to evaluate
the quality of data in clinical warehouses, we queried both STRIDE
and CoagClinic for all the variables used by the IWPC algorithm.
We compared the accuracy of the doses predicted from STRIDE
and CoagClinic with the accuracy achieved in the IWPC research
cohort, which we consider our gold standard. Our goal was not
to simply characterize the potential errors in each particular mea-
surement, but instead to deﬁne a more integrative ‘‘functional” test
of data quality. The clinical dosing algorithm represents such a
functional test. We are thus able to compare the data quality of
the research-grade clinical data with both a general-purpose data-
base based on clinical practice (STRIDE) as well as a special-pur-
pose database also based on clinical practice (CoagClinic). As a
result, we can compare not only the functional data quality of re-
search-grade data to clinical practice data (IWPC gold standard
vs. STRIDE/CoagClinic), but also the functional data quality of gen-
eral practice data to specialty practice data (STRIDE vs. CoagClinic).
Our results have important implications for cohort-ﬁnding in clin-
ical data-mining efforts.2. Methods
2.1. Patient selection
We queried the STRIDE database and retrieved 1472 patient dis-
charge summariesusingﬁve search terms: ‘‘height”, ‘‘weight”, ‘‘age”,
‘‘race”, and ‘‘warfarin” and/or ‘‘coumadin”. The short excerpts were
thoroughly examined to best ensure that the dose was therapeutic.
Thepatient selectionprocedure is shown inFig. 1. First, duplicatepa-
tient records were removed so that each patient in the analysis was
unique. Patientswere excluded if the text record indicated that they
were recently starting or stopping warfarin treatment, if they were
only going to be on warfarin for a short period of time (i.e. prior to
surgery), if their warfarin dose had just changed or was unstable, if
the wording of the record was ambiguous, or if no warfarin dose
was available. Next, we excluded patients taking 5 mg/day, which
is the standard starting dose of warfarin and hence not clearly ther-
apeutic.We also did not include patients taking 1 mg/day,which is a
standard ﬁxed dose for indications such as PICC catheter placement.
After manual examination, 357 records were selected with clearly
speciﬁedwarfarin doses. Of these records, 335 had all the necessary
variables to predict awarfarin dose using the IWPC clinical equation
(height, weight, age, and race).
For the CoagClinic database, we analyzed 104 patient records.
These data are not aggregated into STRIDE and so represent a sep-
arate, non-overlapping set of data. It is possible that some patients
appear in both CoagClinic and STRIDE, but our process of de-iden-tiﬁcation did not allow us to determine this. In any case, the data in
STRIDE and CoagClinic was independently collected. The same
variables were extracted from this clinical database.
2.2. Data analysis
For each patient in the STRIDE and CoagClinic cohorts, a thera-
peutic warfarin dose was predicted using the IWPC clinical algo-
rithm. Next, the mean absolute error, the average difference
between the predicted dose and actual dose, was calculated for
the IWPC clinical algorithm. Finally, the performance of the clinical
algorithm was assessed by computing the percent of patients for
whom the predicted dose was more than 1 mg/day greater than
the actual dose (henceforth referred to as high dose), within
1 mg/day of the actual dose (ideal dose), and more than 1 mg/day
less than the actual dose (low dose). The 1 mg/day cut-off was used
since the IWPC had determined it to be clinically signiﬁcant. In or-
der to compare the number of patients with either a high, ideal, or
low dose in the different patient populations, we used R (version
2.9.1) to perform chi square tests. The following combinations
were analyzed: STRIDE vs. CoagClinic, STRIDE vs. IWPC, and Coag-
Clinic vs. IWPC. To meet the more stringent criteria for multiple
comparisons, a p-value under 0.05/3 = 0.017 was needed.
3. Results
3.1. Results for the STRIDE database
For the STRIDE cohort, the characteristics of the 335 patients are
listed in Table 1. The mean absolute error (MAE) with the IWPC
algorithm was 14.1 mg/wk (Table 2). The clinical algorithm
showed 29.6% of patients with an ideal dose, 34.3% with high doses,
and 36.1% with low doses (Fig. 2).
Table 1
STRIDE, CoagClinic, and IWPC patient populations.
Table 2
Mean absolute error values for the STRIDE, CoagClinic, and IWPC databases.
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In the CoagClinic cohort, we studied 104 patients (Table 1). The
mean absolute error of the clinical equation was 10.4 mg/wk (Ta-
ble 2). The clinical algorithm also showed 54.7% of patients with
an ideal dose, 14.0% of patients with a high dose, and 31.4% of pa-
tients with a low dose (Fig. 2). Next, we compared the number of
low, ideal, and high doses for the IWPC clinical algorithm using
either the STRIDE cohort or the CoagClinic cohort (black vs. gray),
yielding a v2 value of 24.3 (p = 5.2  106).
3.3. Comparison with IWPC cohort
In the original IWPC cohort of 5052 patients (Table 1), the mean
absolute error of the clinical equation was 10.1 mg/wk (Table 2).
The clinical algorithm demonstrated 46.6% of patients with an ideal
dose, 25.7% of patients with a high dose, and 27.7% of patients with
a low dose (Fig. 2). We compared the number of low, ideal, and high
doses for the IWPC clinical algorithm using either the STRIDE co-
hort or the IWPC cohort (black vs. white), yielding a v2 value of
36.9 (p = 9.6  109). Comparing low, ideal, and high doses be-
tween the CoagClinic cohort and the IWPC cohort (gray vs. white)
yielded a v2 value of 6.8 (p = 0.033), which was not under the
threshold for multiple comparisons (p = 0.017).4. Discussion
4.1. Utility of the clinical databases for exploratory analyses
Our results demonstrate that clinical warehouses can have data
of high ‘‘functional” quality, in the sense that the CoagClinic data
nearly matched IWPC research-grade data in its ability to predict
warfarin dose. In addition, the distribution of low, ideal, and high
doses was signiﬁcantly different between STRIDE and the Coag-
Clinic, but far closer between CoagClinic and the IWPC gold stan-
dard research cohort. Thus, although the general clinical database
had data that could be used for estimating warfarin dosing, the
noise in this data was considerably greater than the noise in an-
other clinical practice database that was more closely focused on
warfarin. In many ways, this is not surprising, but it provides a
quantitative estimate of how much noise is introduced by clinical
practice under two scenarios: close clinical attention to the vari-
ables of interest (almost no additional noise over research-grade
data) and general clinical practice without speciﬁc focus (consider-
able additional noise).
When the results from STRIDE are compared to those from the
CoagClinic, it is obvious that the signal is weaker. CoagClinic hadlower mean absolute errors than STRIDE after applying the clinical
dosing algorithm (Table 2). In addition, the MAE value for the Coag-
Clinic cohort was close to the corresponding value for the IWPC co-
hort, but the MAE for the IWPC clinical algorithm was 40% greater
for the STRIDE cohort compared to the IWPC cohort. Compared to
CoagClinic, STRIDE had fewer patients within 1 mg/day of the ac-
tual dose, deﬁned as having an ideal dose, and thus had more out-
liers (Fig. 2). When the distribution of low, ideal, and high doses is
compared between the STRIDE and CoagClinic databases using the
IWPC clinical algorithm, thus comparing the same algorithm on the
two patient populations, the difference is substantial and signiﬁ-
cant (p = 5.2  106).
When the aforementioned distributions are compared between
the STRIDE and IWPC cohorts, the differences are againhighly signif-
icant (p = 9.6  109), with a greater proportion of patients having
an ideal dose using the IWPC cohort. When the same distributions
are compared between the CoagClinic and IWPC cohorts, the differ-
ences are only nominally signiﬁcant (p = 0.033) and not under the
threshold for multiple comparisons (p = 0.017). Interestingly, the
CoagClinic cohort appears tohave slightlymorepatientswithan ideal
dose even compared to the IWPC (Fig. 2). One potential reason why
the IWPC algorithm does not work as well in the IWPC population is
that algorithms tend to bemore accuratewithin cohorts, rather than
across cohorts. The CoagClinic represented one patient population
using a single database,while the IWPC study included 23 sites from
around the world with different data collection procedures. In addi-
tion, since the IWPC study contained a greater proportion of Asian
patients, who on average have a lower warfarin dose [9], this could
have impacteddose prediction, as the averagedose in the IWPCpop-
ulation was slightly lower (Table 1). In any case, these data indicate
that the distribution of dosing patterns is far more similar between
the IWPCandCoagClinic cohorts (p > 0.017) compared to the STRIDE
and CoagClinic cohorts (p < 105).
Overall, the ﬁndings of this study are more likely due to differ-
ences in the quality of data collection rather than underlying differ-
ences in the patient populations fromwhich the data was collected.
The patient populations for STRIDE and CoagClinic were highly sim-
ilar (Table 1). The mean stable dose for STRIDE was 35.7 ± 19.5 mg/
wk, and the mean stable dose for CoagClinic was 35.4 ± 15.8 mg/
wk, which was not statistically different using a t-test (p = 0.89).
Additional statistical comparisons between CoagClinic and STRIDE
included the following: age (p = 0.33), weight (p = 0.56), height
(p = 0.59), and race (p = 0.025, not signiﬁcant after adjusting formul-
tiple comparisons). Despite these similarities, STRIDE and CoagClin-
ic showed large differences in MAE and dosing patterns (Table 2,
Fig. 2). Comparing the IWPC and CoagClinic (Table 1), the mean sta-
ble dose for the IWPC was 30.8 ± 16.8 mg/wk and the mean stable
dose for CoagClinic was 35.4 ± 15.8 mg/wk, which was statistically
different (p = 0.0055). Additional comparisons between the IWPC
and CoagClinic included the following: age (p = 0.56), weight
(p = 0.16), height (p < 0.0001), and race (p = 0.0025). Despite these
differences, the IWPC and CoagClinic demonstrated very similar
MAE values (Table 2), while the CoagClinic had somewhat better
performance when measuring ideal dosing patterns (Fig. 2).
Fig. 2. IWPC clinical algorithm applied to the STRIDE, CoagClinic, and IWPC databases.
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had reached a stable dose based upon short clinical excerpts, espe-
cially without a history of INR values, so this was certainly a source
of noise. CoagClinic, which was designed with hematology in mind,
provides the dose and INR value associated with every visit, mak-
ing it easy to determine whether patients had reached a stable
dose. Moreover, the discharge summaries written for STRIDE were
likely written by physicians who had less experience with antico-
agulation than the staff at the Stanford Oral Anticoagulation Clinic.
While an additional method for validating these results would in-
volve manual chart abstraction of the de-identiﬁed records from
STRIDE, doing this would require more extensive IRB approval.
This analysis excluded patients who were taking exactly 5 mg/
day of warfarin, as it was far more likely that those discharge sum-
maries reﬂected patients who had just started on warfarin and
hence had not reached a stable therapeutic dose. However, some
patients may by chance happen to be therapeutic at 5 mg/day, so
they would have been excluded by this analysis. According to the
data in the CoagClinic database, only 5.8% of the patients were
therapeutic at 5 mg/day, so it is unlikely that this adjustment intro-
duced large bias. Finally, patients taking 1 mg/day were excluded,
as this is a standard ﬁxed dose for certain indications, such as cath-
eter placement, that is not adjusted on subsequent visits. For com-
parison, in the CoagClinic database there were no patients taking
1 mg/day. It should also be noted, however, that our results are
particularly striking because the CoagClinic most likely serves pa-
tients that are generally more difﬁcult to dose, so the good perfor-
mance of the extracted data is even more impressive and
potentially an underestimate of its data quality.
4.2. Opportunities for the improvement of clinical databases for
research
This study offers a number of suggestions for the improvement of
clinical databases, especially as a tool for research. Of course, data
shouldbeexplicitly codedwith controlled, searchable terminologies
whenever feasible. In this case, height, weight, and dose had to be
manually extracted from the text, which was time-consuming for1472 records. This was problematic since many of the query results
did not yield an explicit numerical value for these variables. For in-
stance, a recordmight have contained the word ‘‘weight” in it with-
out listing a numerical value, and the query would have interpreted
the record as if it hada value forweight.On theotherhand, values for
age and racewere automatically provided by the query, so these val-
ueswere nevermissing. In addition, there should be options for spe-
ciﬁcally searching pharmacy data (i.e. drugs, doses, and frequency)
as well as laboratory values (i.e. INR).
A long term advantage of a warehouse like STRIDE is the ability
to gather a much wider range of potentially relevant data than is
available in a specialty-focused clinical database. The focused data-
base only collects variables known to be useful, and thus is limited
in its utility for discovery. Our results suggest that large scale
data-mining efforts in general-purpose clinical databases may see
a degradation of signal of as much as 40%. However, it is important
to note that the amount of signal degradation is also affected by
differences in the capture and representation of data, as some dat-
abases contain free text, while others have a more structured mod-
el for capturing data. In our study, the STRIDE database was a
better example of the free-text model, and the structured organiza-
tion of data in the CoagClinic database likely improved its perfor-
mance. This issue is particularly important for efforts such as
those within the eMerge Network, a consortium that seeks to com-
bine genetic data and data from electronic medical records, and
dbGaP, a public repository of genotypic and phenotypic data,
which are examples of resources that could be used for such stud-
ies in the future [1,2].
5. Conclusions
Ultimately, this study found that clinical warehouses can
certainly provide data that is comparable to research-grade
data, but high-quality data is more likely when extracted from
cohorts who are in clinical settings where the data of interest is
clinically critical. It is not surprising that the quality of warfarin-
related data in a warfarin clinical database is much better than
the quality of warfarin-related data in a general-purpose clinical
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large clinical data warehouses should take special care to ﬁlter
for the clinical setting in which the data was collected in order to
best ﬁnd reliable data, using the clinical practice relevance as a
proxy for data quality.
Our results can be extended by assessing the quality of data
retrieved by other clinical databases, either by studying warfarin
dose or any other clinical outcome. The American Recovery and
Reinvestment Act has authorized approximately $38 billion for
health-related information technology between 2009 and 2019,
and provides an ideal opportunity to build and validate clinical
data collections for research and discovery [10].
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